Voyager Therapeutics, Inc. Available-for-sale Securities, Amortized Cost Basis
Voyager Therapeutics, Inc. (VYGR) had Available-for-sale Securities, Amortized Cost Basis of $78.62 million as of 2017-09-30, per its 10-Q filed 2017-11-02.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-03-14
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $78.62M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $76.29M.
- 2017-03-31: Available-for-sale Securities, Amortized Cost Basis $115.37M.
- 2016-12-31: Available-for-sale Securities, Amortized Cost Basis $139.06M.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2017-09-30 | $78.62M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $76.29M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $115.37M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $139.06M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $128.86M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $202.36M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $213.09M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $193.29M 10-Q · filed 2016-11-10 | $222.89M 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |